Clinical trials: COVID-19; Immunity
COVID-19
Role of HLA Genes and Innate Immunity in the Phenotypic Variability of COVID-19
Case-control, prospective retrospective association study of patients infected with SARS-CoV2 and cured by COVID19. Recruited patients were divided into two cohorts (cases: patients with respiratory failure that required…
- Trial name
- 3490 (NCT05711836)
- Testing
- HLA-genotyping
- Where
- Italy
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19
Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain
The level of neutralizing antibody was detected by using the constructed pseudovirus covid-19 variant at baseline , 1 month , 6 months and 12 months after primary vaccination, within 15 days after booster immunization at 12…
- Trial name
- NCT05087277
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Vaccine Response, COVID-19 Vaccine
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine.
- Conditions
- Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination
- Trial name
- NCT06821100
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Long COVID-19
Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms
We investigated the association between immune system responsibilities in Long COVID patients and Full recovery patients.
- Trial name
- NCT05484700
- Where
- Thailand
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Influenza, Human+COVID-19
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection.
- Trial name
- NCT07464314
- Testing
- Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
- Where
- 12 sites in United States
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
COVID-19
Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults
This is a multicenter, parallel groups, partially randomized, open-label, blank-controlled adaptive platform study to evaluate the effectiveness of a second COVID-19 vaccine booster in Chinese adults who are charactered as the…
- Trial name
- NCT05855408
- Testing
- Intramuscularly administered Ad5-nCoV vaccine, Aerosolized Ad5-nCoV, DelNS1-2019-nCoV-RBD-OPT1
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Relapsing Multiple Sclerosis
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a…
- Trial name
- NCT04847596
- Testing
- Ofatumumab, Covid-19 vaccine
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using…
- Trial name
- NCT06919796
- Testing
- COMIRNATY®
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
COVID-19
Bank of Human Leukocytes From COVID-19 Convalescent Donors With an Anti-SARS-CoV-2 Cellular Immunity
The SARS-CoV-2 identified in China in January 2020 is the cause of an unprecedented pandemic. The SARS-CoV-2 and each viral variant are responsible of a respiratory infectious disease, which can be asymptomatic.
- Trial name
- COVIBank (NCT05458440)
- Testing
- Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Central Hospital, Nancy, France
MIS-C Multisystem Inflammatory Syndrome in Children
Immun Response in Children With MIS-C
Multi-system inflammatory syndrome in children (MIS-C) is a post-viral inflammatory vasculopathy of children and adolescents following Covid-19 infection. It affects one of 1000-5000 children.
- Trial name
- NCT05052424
- Testing
- Analysis of cytokines and immun cell related markers
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Cologne
COVID, SARS-CoV 2
COVID-19: Herd Immunity Study in the Czech Republic
The aim of the SARS-CoV-2-CZ-Preval study is to quantify the prevalence of individuals with a history of SARS-CoV-2 coronavirus infection in the Czech population, except for those diagnosed with COVID-19 by methods based on…
- Trial name
- SARSCoV2CZPrev (NCT04401085)
- Testing
- SARS-CoV-2 diagnostic rapid test, Quantitative analysis of SARS-CoV-2 antibodies
- Where
- Czechia
- Volunteers
- 27,000 people, healthy volunteers welcome
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic
Multiple Sclerosis
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Vaccine responses in patients treated with anti-CD20 antibodies (ocrelizumab and ofatumumab) or S1P receptor modulators (fingolimod and siponimod) were evaluated before and after third SARS-CoV-2 vaccination as part of an ongoing…
- Trial name
- NCT05950308
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Covid19
Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19
Age is the main risk factor associated with the severity of COVID-19. From the beginning of the vaccination campaign, elderly subjects are part of the priority population.
- Trial name
- COVIMMUNAGE (NCT05047718)
- Testing
- COVID-19 vaccine Pfizer (3 doses), COVID-19 vaccine Pfizer (2 doses), COVID-19 mRNA Vaccine Moderna (3 doses)
- Where
- 2 sites in France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Cancer, Hematopoietic System--Cancer
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy.
- Conditions
- Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer, Solid Tumor Malignancy
- Trial name
- NCT05164016
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Multiple Sclerosis
Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab
Phase IV, 3-armed, prospective, open-label, single-center, Israeli study, examining the response to SARS-CoV-2 vaccination in 30 teriflunomide-, 10 alemtuzumab-treated patients, and 30 age-matched (for the teriflunomide group)…
- Trial name
- NCT05075499
- Testing
- COVID-19 vaccination
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- Sheba Medical Center
Children With Cancer, SARS-CoV-2 Infection
Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness
The main goal of this study is to characterize the adaptive immune responses to SARS-CoV-2 infection in a cohort of children with cancer and impaired immune responsiveness and prolonged viral shedding of SARS-CoV-2, and to…
- Trial name
- NCT05172063
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
COVID-19
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
This is a phase Ⅳ follow-up clinical trial based on the previous Phase Ⅳ clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05329038
- Testing
- Inactivated COVID-19 Vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID, SARS-CoV-2
Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity)
The aim of the SARS-CoV-2-CZ-Immunity study is to determine the time profile of the presence of antibodies against SARS-CoV-2 in blood plasma by quantification of antibodies or performing a rapid test in COVID-19 cured patients.
- Trial name
- SARSCoV2CZImun (NCT04453280)
- Testing
- Quantitative analysis of anti-SARS-CoV-2-antibodies, SARS-CoV-2 diagnostic rapid test
- Where
- Czechia
- Volunteers
- 695 people
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic
SARS-CoV-2 Infection
Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2
Introduction: In late 2019, a novel human coronavirus was detected in Wuhan, China, causing an outbreak of the severe acute respiratory syndrome - Coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04987554
- Testing
- glycophosphopeptical AM3
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- University of Valladolid
Immunogenicity, Hematological Malignancies
Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies
Covid-19 is associated with a mortality rate of 33-37% in patients with hematological malignancies. At present, the anti-SARS-CoV-2 vaccination represents the most effective strategy for the prevention of Covid-19.
- Conditions
- Immunogenicity, Hematological Malignancies, Covid-19, Vaccine Response Impaired
- Trial name
- NCT04878822
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Ospedale di Circolo - Fondazione Macchi